Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007;78(4):334-7.
doi: 10.1159/000100838.

Prostate cancer screening with prostate-specific antigen in hemodialysis patients

Affiliations
Clinical Trial

Prostate cancer screening with prostate-specific antigen in hemodialysis patients

Minoru Horinaga et al. Urol Int. 2007.

Abstract

Background/aims: The diagnostic validity of prostate-specific antigen (PSA) among men receiving hemodialysis (HD) has not been well defined. The aim of this study was to evaluate PSA levels in HD men and to compare them with those of non-uremic controls.

Methods: PSA levels were measured in 620 HD men (40-89 years old, mean age 62.4 years). In patients with PSA >4.1 ng/ml, prostate biopsies were performed. Cancer-free men were defined as having PSA ranging between 0 and 4.0 ng/ml, or PSA >4.1 ng/ml but with a pathologically negative biopsy. The resulting data was compared with that for 3,636 non-uremic controls (55-59- (n = 468), 60-69- (n = 2,220), and 70-79-year-old men (n = 948)).

Results: Of 45 HD men with PSA >4.1 ng/ml, 22 consented to undergo a biopsy. Ten were positive and 12 were negative. The mean PSA of cancer-free HD men of 50-59 (n = 159), 60-69 (n = 214), 70-79 (n = 116), and 80-89 (n = 30) were 1.0, 1.0, 1.3, and 2.1 ng/ml, respectively. Cancer-free HD men demonstrated significantly lower PSA compared to controls.

Conclusions: HD men had lower PSA levels than those of controls.

PubMed Disclaimer

Substances